Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
14.4M
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
13M
-
Shares change
-
-101K
-
Total reported value, excl. options
-
$242M
-
Value change
-
-$5.56M
-
Put/Call ratio
-
0.89
-
Number of buys
-
55
-
Number of sells
-
-74
-
Price
-
$18.63
Significant Holders of Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) as of Q3 2023
146 filings reported holding ANIK - Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q3 2023.
Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13M shares
of 14.4M outstanding shares and own 90.16% of the company stock.
Largest 10 shareholders include Trigran Investments, Inc. (2.22M shares), BlackRock Inc. (1.42M shares), Caligan Partners LP (1.08M shares), DIMENSIONAL FUND ADVISORS LP (860K shares), VANGUARD GROUP INC (768K shares), BOOTHBAY FUND MANAGEMENT, LLC (618K shares), RENAISSANCE TECHNOLOGIES LLC (589K shares), MILLENNIUM MANAGEMENT LLC (575K shares), STATE STREET CORP (339K shares), and ACADIAN ASSET MANAGEMENT LLC (336K shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.